CTi Biopharma — Investor Presentation (September 2014)
27 slides from CTi Biopharma's investor presentation, Sep 16, 2014
Slide 1: Corporate Presentation
Exhibit 99.1 CORPORATE PRESENTATION September 2014
Slide 2: Forward Looking Statement
Forward Looking Statement This presentation includes forward-looking statements within the meaning of the Safe Harbor provisions of the Private Securities Litigation Reform Act of 1995. Such statements are subject to a number of risks and uncertainties, the outcome of which could materially and/or a
Slide 3: CTI BioPharma Opportunity
CTI BioPharma Opportunity Marketed Oncology Product & Late Stage Pipeline PIXUVRI ®: Marketed in 10 E.U. Countries • 1 st approved therapy in the E.U. for relapsed aggressive B-cell NHL beyond 2 nd line • Partnership goal: expand market potential, upfront & cost share; retain U.S./E.U. rights Pacrit
Slide 4: Therapeutic Focus: Novel Targeted Therapies
Therapeutic Focus: Novel Targeted Therapies Blood-Related Cancers MPNs Leukemia Lymphoma Myelofibrosis AML and MDS Aggressive NHL 4
Slide 5: ‘06 for concentrate for
‘06 for concentrate for uton for infusion xCti BIOPHARMA
Slide 6: PIXUVRI: Overview
PIXUVRI®: Overview One of the most active agents in R/R aggressive B-cell NHL where there is no standard therapy • 1 st and only approved mono-therapy in the E.U. for aggressive B-cell NHL 3 rd/4 th line • Novel MOA: DNA alkylation/mitotic instability • Works in anthracycline-resistant aggressive B-
Slide 7: Relapsed Aggressive NHL: High Unmet Need
Relapsed Aggressive NHL: High Unmet Need ~37,000 new cases in the E.U. each year1,2 • Typically Anthracycline-based treatment • Anthracyclines limited mostly to 1 st line use due to association with 1 st Line irreversible, cumulative dose related heart damage3,4 • Intensive non-anthracycline based t
Slide 8: PIXUVRI Highlights
PIXUVRI Highlights rd Only randomized controlled Phase 3 trial in 3 -line aggressive NHL (n=140 patients) rd th ITT Population 3 /4 line B-cell Results PIXUVRI Comparator PIXUVRI Comparator p value p value (n=70) (n=70) (n=50) (n=49) CR/CRu 24% 7.1% 0.009 CR/CRu 28% 4.0% 0.002 ORR 40% 14.3% 0.001 OR
Slide 9: PIXUVRI: E.U. Commercial Update
PIXUVRI: E.U. Commercial Update Attractive Market Opportunity nd rd nd 2 salvage (3 line) = 2 chance at potentially curative ASCT* 13,500** addressable market Potential >8,000 patients on product at peak in E.U.** Label expansion study underway (PIX306) Reimbursement in Key Major Market Countries Re
Slide 10: PIXUVRI: PIX306 Study
PIXUVRI: PIX306 Study Post-marketing commitment Phase 3 study Eligibility Criteria Pixantrone* Primary Endpoint 1:1 Rituximab PFS Relapse after CHOP-R therapy or an equivalent Randomization regimen and are Secondary n = ~220 Gemcitabine* Endpoints ineligible for stem cell transplant Rituximab CR ORR
Slide 11: Pacritinib
Pacritinib
Slide 12: Myelofibrosis: A Chronic Disease
Myelofibrosis: A Chronic Disease • Malignant bone marrow disorder triggers an inflammatory response, scarring the bone marrow and limiting its ability to produce blood cells prompting the spleen and liver to compensate • Symptoms include: enlargement of the spleen, anemia, thrombocytopenia, extreme
Slide 13: Thrombocytopenia in Myelofibrosis
Thrombocytopenia in Myelofibrosis Clinical trials of JAK inhibitors before PERSIST excluded patients with platelet counts <100,000/µL or <50,000/µL • 92% patients in COMFORT II (ruxolitinib) had normal platelet counts 1 Treatment emergent thrombocytopenia is a limitation of most JAK1/JAK2 inhibitors
Slide 14: Pacritinib Phase 2: Treatment Duration Independent of Platelet Counts
Pacritinib Phase 2: Treatment Duration Independent of Platelet Counts Baseline Baseline Platelets Platelets All 100,000/µL 100,000/µL (n=65) (n=28) (n=37) Platelet Count (x10 3/µl) 59 227 121 Median (IQR) (34-70) (163-315) (60-238) Range 15-97 104-859 15-859 Duration on Treatment Median Weeks 46.9 (
Slide 15: Pacritinib Phase 2: Spleen Response Independent of Platelet Counts
Pacritinib Phase 2: Spleen Response Independent of Platelet Counts Baseline Baseline Time Platelets Platelets All Endpoint Period 100,000/µL 100,000/µL (n=65) (n=28) (n=37) 35% Up to 24 13 / 49 7 / 23 (30%) 6 / 26 (23%) Reduction weeks (27%) in spleen volume by Up to last 18 / 49 MRI visit on 10 / 2
Slide 16: 50% Reduction In Patient-Reported Symptom Score Independent of Platelet Counts
50% Reduction In Patient-Reported Symptom Score Independent of Platelet Counts* Baseline Baseline All Platelets Platelets (n=65) 100,000/µL 100,000/µL (n=28)** (n=37)** Up to 24 weeks 11 / 28 (39%) 16 / 34 (47%) 27 / 62 (44%) Up to last visit on 13 / 28 (46%) 17 / 34 (50%) 30 / 62 (48%) treatment *
Slide 17: Pacritinib: Addressing Unmet Need in MF
Pacritinib: Addressing Unmet Need in MF Fast Track Designation; Phase 3 Program Underway PERSIST-1 • Topline results expected early 2015 • Most inclusive randomized trial of MF patient population representative of actual clinical practice - INT-1, 2 High risk, no restrictions on platelet counts PERS
Slide 18: Pacritinib: PERSIST-1 Phase 3
Pacritinib: PERSIST-1 Phase 3 Eligibility Criteria No exclusion for Pacritinib Primary Endpoint platelet levels, 2:1 stratified for platelet % of patients achieving Randomization* 35% reduction in counts of 100,000/µL and 50,000/µL n = ~320 Best Available spleen size from Therapy (BAT) baseline to W
Slide 19: Pacritinib: PERSIST-2 Phase 3
Pacritinib: PERSIST-2 Phase 3 Co-Primary Endpoints Pacritinib % of patients achieving 400 mg QD Eligibility Criteria 35% reduction in spleen volume from 1:1:1 Patients with platelet Pacritinib baseline to Week 24 Randomization * 200 mg BID counts 100,000/µL, prior/current JAK2 n = ~300 Patients achi
Slide 20: Pacritinib: Collaboration with Baxter
Pacritinib: Collaboration with Baxter • Announced November 2013 • CTI and BAXTER: Joint commercialization, profit split in U.S. • BAXTER: Exclusive rights to commercialize in all indications outside U.S., BAXTER generally responsible for 75% of global development program Summary of Financial Terms •
Slide 21: Pacritinib: Key Takeaways
Pacritinib: Key Takeaways • Oral JAK2/FLT3 inhibitor that lacks treatment emergent myelosuppression associated with marketed JAK1/JAK2 agent - Potential to demonstrate superior disease and symptom control over titrated doses of ruxolitinib - May be used in combination regimens w/o overlapping myelos
Slide 22: Tosedostat
Tosedostat
Slide 23: Tosedostat
Tosedostat Novel Treatment for Blood-Related Cancers: MDS & AML • Oral, once-daily, aminopeptidase inhibitor interferes with protein recycling, prevents breakdown of peptides into amino acids necessary for tumor cell survival • Synergy with targeted agents (HMA, proteosome inhibitors) or chemotherap
Slide 24: Financial Overview
Financial Overview Capital Structure and Financial Statistics Exchanges NASDAQ and MTA: CTIC Market Capitalization* ~$390mm Shares Outstanding ~149.9mm Pro Forma Cash as of June 30, 2014** $53.2mm Debt (unsecured) $15mm *As of September 12, 2014 stock price of $2.61 per share **In August 2014, CTI r
Slide 25: 2014 Key Business Priorities
2014 Key Business Priorities Initiate PERSIST-2 (2 nd Phase 3 trial of pacritinib in MF) Earn $20mm milestone from BAXTER after completion of enrollment in PERSIST-1 Be in position to report PERSIST-1 top-line results in 1Q-2015 • Secure ROW partner (ex-U.S.) to expand commercial potential for PIXUV
Slide 26: Why Invest in CTI BioPharma
Why Invest in CTI BioPharma Biopharmaceutical company with a marketed oncology drug in the E.U. Strategic partner provides validation, financial resources and commercial support for high-potential JAK2/FLT3 inhibitor Phase 3 program Building value through development of late-stage pipeline, with emp
Slide 27: Thank You!
THANK YOU! Ctl BIOPHARMA NASDAQ & MTA: CTIC
CTI BioPharma — Investor Presentation (September 2014) on 6ix